pyrimidinones and Ventricular-Dysfunction

pyrimidinones has been researched along with Ventricular-Dysfunction* in 1 studies

Other Studies

1 other study(ies) available for pyrimidinones and Ventricular-Dysfunction

Article	Year
Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction. Japanese circulation journal, 2001, Volume: 65, Issue:1 Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction. Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Potassium Channel Blockers; Pyrimidinones; Tachycardia; Ventricular Dysfunction	2001

Article

Year

Initial experience with nifekalant hydrochloride (MS-551), a novel class III antiarrhythmic agent, in patients with acute extensive infarction and severe ventricular dysfunction.

Japanese circulation journal, 2001, Volume: 65, Issue:1

Nifekalant hydrocholoride, a novel class III antiarrhythmic agent, was used as the treatment in 4 patients with extensive anterior infarction and severe ventricular dysfunction. The malignant ventricular tachyarrhythmia was effectively suppressed at a relatively low dose, without compromising the hemodynamics, indicating that this potent K+ channel blocker has therapeutic potential for acute myocardial infarction.

Topics: Aged; Anti-Arrhythmia Agents; Electrocardiography; Hemodynamics; Humans; Male; Middle Aged; Myocardial Infarction; Potassium Channel Blockers; Pyrimidinones; Tachycardia; Ventricular Dysfunction

2001